Core Viewpoint - Zhuhai Tainuo Maibo Pharmaceutical Co., Ltd. has officially submitted its IPO application to the Shanghai Stock Exchange, marking the first acceptance under the newly restarted fifth listing standard for the Sci-Tech Innovation Board [1] Group 1: Company Overview - Tainuo Maibo, established in 2015, is an innovative biopharmaceutical company focused on the development of innovative biological drugs [2] - The company reported revenues of 4.34 million yuan, 0 yuan, 15.06 million yuan, and 169,300 yuan for the years 2022 to the first quarter of 2025, with net losses of 429 million yuan, 446 million yuan, 515 million yuan, and 177 million yuan during the same period [2] Group 2: IPO Details - The company aims to raise 1.5 billion yuan through its IPO, which will be allocated to new drug research and development, expansion of antibody production facilities, and supplementing working capital [1] - Huatai United Securities is the sponsor for this IPO [1] Group 3: Market Context - The acceptance of Tainuo Maibo's application further validates the practicality of the fifth listing standard, which is designed for unprofitable companies with certain revenue scales, providing a pathway for innovative drug companies in their early commercialization stages [1] - The "1+6" new policy introduced on June 18 supports high-quality unprofitable technology companies in going public, including the reintroduction of the fifth listing standard and the expansion of its applicability [1]
科创板第五套上市标准重启后首家！泰诺麦博拟募资15亿元冲刺科创板IPO
Xin Hua Cai Jing·2025-08-01 01:55